Archives June 2026

Business Wire India

Following the introduction of its “Future Landing” vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/

 

 

 

Rack-Scale Infrastructure, Validated for AI Factories

 

At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories.

 

 

Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader rack-scale portfolio. Alongside its rack-scale platforms, GIGABYTE also presents GAIFA (GIGABYTE AI Factory Accelerator), a purpose-built AI factory in Taiwan where next-generation compute, high-speed networking, and NVIDIA’s software stack are integrated into a fully validated environment for system verification, workload optimization, and deployment readiness.

 

 

At the operational layer, GPM (GIGABYTE POD Manager) provides unified visibility and infrastructure-level monitoring across compute, networking, cooling, and power systems, enabling AI factories to operate and scale as a coordinated system.

 

 

Infrastructure Built for Accelerated Deployment

 

 

To accelerate deployment beyond conventional data center construction, GIGABYTE introduces GADU (GIGABYTE Accelerated Deployment Unit), a modular AI infrastructure platform that integrates high-density compute, advanced cooling, and power distribution into transportable, deployment-ready systems. Supporting direct liquid cooling and immersion cooling architectures, GADU enables organizations to expand AI capacity with significantly reduced deployment timelines while maintaining flexibility across diverse operational environments.

 

 

Together with GIGABYTE’s rack-scale systems and infrastructure software, GADU transforms infrastructure into a scalable, rapidly deployable platform.

 

 

Physical AI from Simulation to Action

 

 

Demonstrating how AI moves beyond simulation and into real-world operation, GIGABYTE presents a complete real-to-sim-to-real workflow built on NVIDIA’s full-stack AI platforms.

 

 

The workflow begins with high-fidelity digital twins built through NVIDIA OVX systems, powered by the XLS4-SX2-LAS1 platform on NVIDIA MGX™ architecture with RTX™ PRO GPUs for large-scale Omniverse simulations. AI training then advances through the G2L4-SD4-LA08 platform on NVIDIA HGX™ architecture, where synthetic data generation and reinforcement learning take place. Once validated, trained models are deployed to edge systems powered by NVIDIA Jetson for real-time robotic control, brought to life through live demonstrations alongside Isaac Sim visualizations.

 

 

Clinical AI at the Point of Care

 

 

GIGABYTE also showcases a growing clinical AI ecosystem for real-time medical inference at the point of care. Working alongside healthcare partners, GIGABYTE integrates BRIX mini PCs with AI-assisted diagnostic systems supporting bone marrow smear classification and real-time polyp detection during colonoscopy. The VFG100, an FPGA-accelerated vision platform, delivers real-time image preprocessing with ultra-low CPU overhead, while AI TOP ATOM enables local inference for pulmonary imaging analysis, meeting healthcare data privacy and compliance requirements.

 

 

Bringing AI Closer to Where Decisions Are Made

 

 

Extending AI beyond centralized infrastructure, GIGABYTE also showcases the W775 workstation and AI TOP ATOM desktop AI supercomputer for private training, model customization, and agentic AI workflows powered by NVIDIA NemoClaw.

 

 

Beyond the main showcase on the 1^st floor, visitors can also explore GIGABYTE’s dedicated exhibit on the 4^th floor, where AI TOP systems and consumer AI innovations demonstrate how GIGABYTE’s computing capabilities extend from AI infrastructure to everyday intelligent experiences. At COMPUTEX 2026, GIGABYTE demonstrates how “Future Landing” is turning AI infrastructure into systems that are ready, deployable, and already happening.

 

 

GIGABYTE@COMPUTEX 2026
https://www.gigabyte.com/Events/Computex
June 2-5, 2026
Taipei Nangang Exhibition Center, Hall 1
Enterprise (1F K0802) | Consumer (4F M0520)

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260525486787/en/

 

Business Wire India

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs.

 

Data from three differentiated BeOne pipeline assets will be presented, including:

 

 

• CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer.
• B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in advanced solid tumors.
• GPC3x4-1BB (BGB-B2033)bispecific antibody (rapid oral presentation): First clinical data in advanced solid tumors, including hepatocellular carcinoma (HCC), the most common type of liver cancer.

 

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “2026 is an inflection year for BeOne’s solid tumor portfolio, marked by the encouraging data we are presenting at ASCO combined with upcoming readouts at other major congresses. These programs validate our strategy of pairing the right biology with the right modality, and support advancing several assets in different indications into pivotal trials in 2026.”

 

Selective CDK4 inhibitor shows promising efficacy and differentiated safety in first-line breast cancer (Poster Presentation: 180; June 1, 2026, 1:30 PM-4:30 PM CDT)
BeOne will present data about its highly selective CDK4 inhibitor, BGB-43395, in 1L HR+/HER2- metastatic breast cancer, in combination with letrozole, showing promising anti-tumor activity and a favorable safety profile, characterized by infrequent low-grade hematologic toxicities and manageable GI events, which were further mitigated when administered with food. Highlights include:

 

 

• The 240 mg dose of BGB-43395 plus letrozole resulted in a confirmed overall response rate (ORR) of 68.4% (95% CI: 43.4–87.4) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
• The 400 mg dose plus letrozole resulted in a confirmed ORR of 63.2% (95% CI: 38.4–83.7) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
• Low levels of hematologic treatment-related adverse events (TRAEs) with Grade ≥3 neutropenia reported in 5.3% of patients at the 240 mg dose level and 0% at 400 mg, as well as low frequency of fatigue and asthenia; supports profile and validates the molecule’s high selectivity for CDK4.
• GI TRAEs were mitigated when administered with food, all of which were Grade 1.
• Median study follow-up was 12.5 (range, 3.1-15.2) months, 12.4 (range, 8.0-15.0) months, and 10.8 (range, 3.2-12.9) months for the 240 mg, 400 mg, and 600 mg dose groups, respectively.

 

These compelling safety and efficacy findings support the rationale to initiate a global, randomized Phase 3 clinical trial with BGB-43395 in combination with letrozole in 1L HR+/HER2- metastatic breast cancer. The trial, KANDELA-302 (NCT07492641), will begin enrolling patients this month.

 

B7-H4 ADC demonstrates encouraging efficacy supporting advancement in ovarian cancer (Rapid Oral Abstract: 3013; June 2, 2026, 9:45-11:15 AM CDT)
Data at ASCO from BeOne’s B7‑H4-targeting antibody-drug conjugate (ADC), BG‑C9074, include results from Phase 1 dose‑escalation and safety‑expansion cohorts, demonstrating a combination of early efficacy signals and a favorable tolerability profile. Highlights include:

 

 

• At doses under consideration for future development, confirmed ORR of 45.5% and unconfirmed ORR of 54.5% in ovarian cancer (OC), and 40.0% in triple-negative breast cancer, with median study follow-up of 6.6 (range, 0.3-20.8) months.
• Anti-tumor activity demonstrated in OC regardless of B7-H4 expression level.
• Treatment was generally well tolerated with low rates of discontinuation at <5%; 31.5% of patients experienced Grade ≥3 TRAEs, with no Grade ≥3 nausea at 6 mg/kg adjusted ideal body weight (AIBW) and 1.2% at 8 mg/kg AIBW. Grade ≥3 neutropenia rates were 14.8% at 6 mg/kg AIBW and 34.6% at 8 mg/kg AIBW.
• AIBW-based dosing used in the ongoing phase 1 study of BG-C9074 effectively reduced pharmacokinetic variability compared with total body weight dosing, as presented in a separate abstract (Poster 166) at ASCO.

 

These results support continued advancement of the BG‑C9074 development program, with efforts focused on early‑line OC and additional B7‑H4-expressing tumor types.

 

Potential first-in-class GPC3x4-1BB bispecific demonstrates unprecedented anti-tumor activity in heavily pre-treated HCC patients (Rapid Oral Abstract: 3016; June 2, 2026, 9:45-11:15 AM CDT)
The first clinical data (Phase 1a) for BGB-B2033, a GPC3x4-1BB bispecific antibody, will be presented in a rapid oral session highlighting the first-in-class potential of this program in advanced solid tumors, including heavily pre-treated HCC. BGB-B2033 was rationally designed to target GPC3-expressing tumors, a protein commonly expressed in HCC, the sixth most prevalent cancer and third leading cause of cancer death worldwide,¹ with five-year survival rates of only approximately 20%.²

 

 

Highlights include:

 

 

• At doses ≥300 mg, confirmed ORR was 28.9% and unconfirmed ORR was 31.6%, with median study follow-up of 4.8 (range, 0.3-15.5) months.
• Treatment was generally well tolerated across all dose levels (1-1000 mg every three weeks [Q3W], N = 61) with no significant dose-dependent increase in rates of treatment-emergent adverse events (TEAEs):
  • 68.9% (42) of patients experienced TEAEs; of these:
    • 47.5% (29) were treatment related
    • 8.2% (5) of patients experienced Grade ≥3 TRAEs
    • 4.9% (3) were treatment-related serious adverse events
  • TEAE leading to treatment discontinuation occurred in 3.3% (2) of patients
  • Dose limiting toxicity occurred in 1.6% (1) of patients
• TRAEs that occurred in >5% of patients were limited to increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both occurring at Grade ≥3 in only 1.6% of patients.

 

BGB-B2033	300 mg Q3W   (N=14)	600 mg Q3W   (N=14)	1000 mg Q3W   (N=10)
Confirmed ORR (complete response + partial response), n (%)	4 (28.6)	5 (35.7)	2 (20.0)
Unconfirmed ORR (complete response + partial response), n (%)	4 (28.6)	5 (35.7)	3 (30.0)*
*An additional PR (week 36) was reported at 1000 mg, with patient still on treatment, pending confirmation in the next tumor assessment

With ORR levels in heavily pretreated patients on par with the current first-line immunotherapy combination standard of care and a differentiated safety profile, BeOne is moving rapidly to advance clinical development of BGB-B2033. The Company has already announced the initiation of a potentially registration-enabling pivotal study in late-line HCC and planned expansion into earlier lines of therapy and additional tumor types, with the ambition to establish a new standard of care in this difficult-to-treat cancer.

 

Investor webcast to highlight solid tumor pipeline data at ASCO

 

 

BeOne will hold an investor webcast at 7:00 p.m. CDT/8:00 p.m. EDT, today, June 1, 2026. The Company’s leadership team, with clinical commentary by expert physicians, will highlight key solid tumor programs being presented at ASCO, share progress in BeOne’s global R&D portfolio, and outline the strategies and capabilities supporting the Company’s continued growth trajectory.

 

 

Webcast access details are available in the Investors section of BeOne’s website at http://ir.beonemedicines.com, https://hkexir.beonemedicines.com, and https://sseir.beonemedicines.com. An archived webcast will be available on the Company’s website.

 

 

About BGB-43395, a CDK4 inhibitor
BGB-43395 is an investigational cyclin-dependent kinase (CDK) 4 inhibitor being studied in a global clinical development program in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The program includes KANDELA-302 (NCT07492641), a randomized Phase 3 clinical trial, initiated in Q2 2026 in first-line metastatic HR+/HER2- breast cancer. BGB-43395 is highly potent and selective CDK4 inhibitor and has the potential to reduce the dose-limiting hematologic toxicities that exist with the current CDK4/6 standard of care and may improve tolerability and enable deeper CDK4 inhibition.

 

 

About BG-C9074, a B7-H4-targeting ADC
BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells. In a Phase 1 study of BG-C9074 (NCT06233942), patients with advanced solid tumors, irrespective of B7-H4 expression, received BG-C9074 every 3 weeks in escalating doses from 1 to 9 mg/kg. A subsequent safety expansion cohort received BG-C9074 in doses ranging from 4 to 8 mg/kg. Endpoints included safety, recommended dose for expansion, preliminary antitumor activity and pharmacokinetic measures.

 

 

About BGB-B2033, a GPC3x4-1BB bispecific antibody
BGB-B2033 is a bispecific antibody targeting GPC3 (glypican 3), a tumor-specific antigen highly expressed in hepatocellular carcinoma (HCC),³ and 4-1BB, a co-stimulatory receptor associated with T-cell activation and tumor reactivity in HCC.⁴ The molecule has been designed with reduced antibody-dependent cellular cytotoxicity (ADCC) to prevent systemic toxicity. BGB-B2033 is being investigated in a Phase 1 study (NCT06427941) in patients with GPC3-expressing advanced solid tumors with at least one prior line of therapy. Patients received BGB-B2033 every 3 weeks in eight escalating dose levels from 1 to 1000 mg, with various safety and anti-tumor activity endpoints. In December 2025, the FDA granted Fast Track Designation to BGB-B2033 for the treatment of HCC, followed by Orphan Drug Designation in March 2026.

 

 

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding its solid tumor pipeline; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit ourNewsroomsite.

 

 

1 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08. PMID: 34422400; PMCID: PMC8343080.
2 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Accessed April 2026.
3 Fanching Lin et al. Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. J Clin Oncol 42, 525-525(2024).DOI:10.1200/JCO.2024.42.3_suppl.525
4 Kim DY et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, VOL. 71, NO. 3, 2020. https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30881

 

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601948824/en/

 

Business Wire India

 

• Procore is the solution to fragmented data, helping ensure information integrity from approved design to handover
• Connects the full project lifecycle in one trusted environment with a single source of truth across BIM, Documents, Quality, and Assets
• Transforms BIM into a live execution workspace via BIM Model Manager, streaming models of any size directly to mobile devices to connect real-time project data with 3D coordination
• Leverages Procore AI with embedded Datagrid capabilities to turn project data into an actionable foundation, powering agentic AI coworkers that can help automate construction workflows and execute work directly within the platform

 

Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, today announced the launch of its connected Common Data Environment (CDE)—a purpose-built CDE from the ground up on a single platform to unify and verify project data from approved design to handover, capturing evidence in the flow of work to help keep the digital record aligned with site reality. This trusted data foundation allows agentic AI to act across the full construction lifecycle.

 

In an industry where fragmented information continues to slow decision-making and contribute to costly delays, connected data is increasingly defining top-performing organizations. New research from Dodge Construction Network* found firms with optimized data practices achieve up to 23% higher productivity, manage 27.8% greater construction volume using the same resources, and reduce project delays by more than six days. Those firms also report up to 40% stronger overall performance, highlighting why a trusted data foundation is becoming essential for AI adoption, operational efficiency, and ultimately, better project execution.

 

 

Procore’s connected CDE directly addresses this challenge—transforming document storage into an active governance environment that connects the approved design to site execution across the full project lifecycle—all powered by AI. For European teams operating under ISO 19650 and the Building Safety Act, this connected record helps provide the defensible audit trail required to meet compliance obligations at every stage.

 

 

“While construction has made significant progress in digitizing workflows, many organizations still operate across disconnected systems and siloed project data,” said Lee Miles, General Manager, Europe, Middle East and Africa (EMEA) at Procore. “The challenge is no longer simply moving from paper to digital, but ensuring information flows consistently across teams, processes and the full project lifecycle. As regulatory expectations rise, projects become more complex, and firms adopt AI, connected data is becoming a competitive advantage. Organizations are moving beyond simple document storage and toward trusted and connected information environments that help improve performance today and enable agentic AI to operate with confidence.”

 

 

Creating the Trusted Environment Required for Agentic AI

 

 

Procore’s CDE creates the foundation for AI to move beyond surfacing information and toward executing work.

 

 

The expanded Procore AI experience embeds Datagrid directly into Procore, introducing agentic AI coworkers designed to automate construction workflows and take action within the platform. Built to help eliminate administrative friction rather than replace professional judgment, this approach accelerates execution while project teams retain control, accountability, and final decision-making authority. These AI capabilities can reason across project context, understand relationships between workflows and data, and support execution in complex construction environments.

 

 

“We’re on track to reduce construction administration work with respect to RFI creation, response, and submittal review by 50%,” said Alain Waha, Chief Technology Officer of Buro Happold. “By embedding AI directly into project workflows, teams can spend less time navigating information and more time advancing the work.”

 

 

By connecting AI to structured project datasets—including BIM models, drawings, specifications, RFIs, submittals, and field activity—Procore AI gains a deeper understanding of both spatial and operational context. This enables teams to turn fragmented project information into immediate, actionable insights.

 

 

The Procore AI experience with Datagrid intelligence embedded directly into the platform can surface answers already contained within project records before new RFIs are created, identify discrepancies between approved designs and field execution, and accelerate issue resolution by connecting related workflows, documents, and historical project context. Tasks that previously required hours of manual searching and coordination can be completed in minutes, with transparent source attribution.

 

 

Unlike horizontal AI tools, Procore AI is purpose-built for construction and grounded in verified project data. When teams encounter coordination challenges, project risks, or emerging safety concerns, Procore AI does more than retrieve information—it helps identify root causes earlier, recommend next actions, and reduce the downstream impacts that drive delays, rework, and cost overruns.

 

 

Procore will be showcasing its new CDE and Procore AI offering at Digital Construction Week (stand D200) in London, June 3-4.

 

 

Market Availability

 

 

Developed specifically for European market requirements, Procore’s CDE will initially launch in the UK and Ireland before expanding across EMEA.

 

 

Procore has established a localized UK Data Zone, with a dedicated EU Data Zone planned for launch in fall 2026. The platform supports key industry standards, including ISO 19650 and the Building Safety Act–with Cyber Essentials certification targeted for year end.

 

 

*Dodge-Procore Research Methodology

 

 

The ‘Quantifying The Value Of Construction Management Software’ study was conducted in 2025 to investigate the return on investment that clients and contractors experience from their use of construction management software. An online survey was used to gather the responses of contractors and clients on whether they experienced 62 specific benefits from their use of the software. Nearly half (45%) of the 62 benefits included a follow-up question on quantifiable outcomes or more detailed findings.

 

 

The survey was fielded by Dodge Construction Network. Procore also invited its users to participate. The findings include users of 11 different brands of construction management software. 688 responses were received from construction management software users in the United Kingdom and Ireland.

 

 

About Procore

 

 

Procore Technologies, Inc. (NYSE: PCOR) is a leading technology partner for every stage of construction. Built for the industry, Procore’s unified technology platform drives efficiency and mitigates risk through AI & data-driven insights and decision making. Over three million projects have run on Procore across 150+ countries. For more information, visit https://www.procore.com/.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601616595/en/

 

Business Wire India

Omdia’s latest TV & Video market data shows global online video subscriptions reached 2.24 billion at the end of 2025, up 17.6% year on year from 1.9 billion in 2024. However, growth is expected to slow to single digits in 2026 as the market enters a more mature phase. Meanwhile, global pay-TV subscriptions continued their gradual decline, falling 1.8% year on year to 1.03 billion. The balance of the global TV and video market continues to shift toward streaming, with online video accounting for 68.4% of the combined 3.3 billion subscriptions worldwide.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529336169/en/

 

 

 

In terms of revenue, online video overtook pay-TV for the first time in 2025, Online video revenue increased 13.5% to $176 billion while pay TV revenue declined 4% to $170 billion. Both figures include subscription and transactional revenue but exclude advertising.

 

Omdia’s global data reflects a wide range of different trends taking place at the local level across the markets it tracks. A key common theme, however, is that new, lower cost, ad-supported tiers have been attracting new subscribers into the online video segment.

 

 

Adam Thomas, Practice Leader, Media, Entertainment & Advertising team, said: “The 17.6% increase in subscriptions in 2025 was the largest annual rise since 2021. That growth was driven, in particular, by subsidized ad-tier subscriptions offered by telcos and pay-TV operators. The popularity of these lower-cost offers is a key factor behind the fact that subscription numbers grew by 17.6%, while revenue increased by a more moderate 13.5%.”

 

 

Another clear trend across the sector is that online video platforms are changing their focus from growing subscriber numbers to maximizing revenue from their existing client base, often through price increases for their premium, non-ad-supported tiers. This trend is expected to remain prominent in the years ahead. While the 2025 figures show that discounted ad-tier pricing can attract significant numbers of cost-conscious subscribers into the online video ecosystem, this will be a short-term phenomenon. With several core online video markets approaching saturation Omdia believes the focus on price rises to maximize profits will result in slower subscription, forecasting 5.6% growth for full-year 2026.

 

 

Tony Gunnarsson, Senior Principal Analyst, TV & Online Video added: “It’s clear that the availability of attractively priced ad-tier options created a temporary uplift in SVOD subscriber numbers in 2025. However, this has not changed our longer-term forecast, which remains for low single-digit annual growth rates for the foreseeable future.”

 

 

ABOUT OMDIA

 

 

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529336169/en/

 

Business Wire India

• AIR 377: Jai Somani (Infinity Learn)

• AIR 500: Shashank Maurya (Sri Chaitanya Academy, Varanasi)

• AIR 769: Nishank Vyas (Sri Chaitanya Academy, Bengaluru)

Infinity Learn by Sri Chaitanya, India’s leading hybrid learning platform, today announced its continued streak of success with remarkable student outcomes in the JEE Advanced 2026 examinations. Excelling across both online and offline learning formats, Infinity Learn has once again showcased the strength of its hybrid learning model in JEE Advanced, one of India’s most competitive and sought-after entrance examinations for admission to premier engineering institutions such as the IITs and IIITs.

Among the top achievers, Infinity Learn’s online student Jai Somani secured an impressive All India Rank (AIR) 377. Adding to the institutional glory, Sri Chaitanya Academy Varanasi offline student Shashank Maurya sealed AIR 500, and Sri Chaitanya Academy Bengaluru student Nishank Vyas secured AIR 769. These consistent rankings reflect the strength of a proven ecosystem that combines Sri Chaitanya’s four decades of academic excellence with Infinity Learn’s technology-driven hybrid learning model, seamlessly integrating online and offline learning experiences.

Commenting on the steady growth trajectory, Sushma Boppana, CEO & Director, Sri Chaitanya Educational Institutions & Founder, Infinity Learn, said: “We are immensely proud to see Infinity Learn emerge as a trusted name in education, delivering consistent results and creating meaningful student success stories year after year across both digital and classroom learning environments. The exceptional performance of our learners reflects their deep dedication and the unwavering commitment of our faculty. As a premier educational institution, we remain deeply invested in democratising education, elevating talent to its fullest potential, and strengthening the trust parents place in us. Congratulations to all our students and their families.”

Expanding on this vision of multi-channel educational delivery, Ujjwal Singh, Founding CEO of Infinity Learn by Sri Chaitanya, added: “At Infinity Learn, outcomes define our ultimate purpose. I am incredibly happy that year after year we continue to strengthen our performance across both our online platform and offline centres, enabling students nationwide to secure opportunities at premier engineering institutions and fulfil their aspirations. Our hybrid model enables students in Tier 2 and Tier 3 cities to access the same high-quality, outcome-driven education as those in major metros, proving that excellence is not defined by geography. Our core promise will always remain: Baccha Sekha ki nahi. I extend my heartfelt congratulations to our students and their families for their outstanding success, and to our faculty for their exceptional dedication and commitment to student outcomes.”

As Infinity Learn continues to scale its hybrid infrastructure, these results cement its position as one of India’s most reliable platforms for admission in top-tier engineering institutes across India.